MediciNova (NASDAQ:MNOV - Get Free Report) issued its quarterly earnings results on Wednesday. The biopharmaceutical company reported ($0.06) earnings per share for the quarter, hitting the consensus estimate of ($0.06), Zacks reports.
MediciNova Trading Up 3.1 %
Shares of MNOV traded up $0.06 during midday trading on Friday, reaching $1.83. 24,296 shares of the stock were exchanged, compared to its average volume of 20,071. The company has a market capitalization of $89.75 million, a P/E ratio of -7.96 and a beta of 0.82. MediciNova has a 52 week low of $1.12 and a 52 week high of $2.55. The company's 50 day moving average is $1.98 and its two-hundred day moving average is $1.85.
Wall Street Analyst Weigh In
MNOV has been the subject of several research analyst reports. StockNews.com assumed coverage on MediciNova in a research report on Wednesday. They set a "hold" rating for the company. D. Boral Capital reiterated a "buy" rating and set a $9.00 price objective on shares of MediciNova in a report on Friday.
View Our Latest Report on MediciNova
About MediciNova
(
Get Free Report)
MediciNova, Inc, a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. It is developing MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent for treating neurological and other disorders, such as primary and secondary progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and substance dependence and addiction, as well as prevention of acute respiratory distress syndrome, and long COVID.
Further Reading
Before you consider MediciNova, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and MediciNova wasn't on the list.
While MediciNova currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
